Trevena (NASDAQ: TRVN) announced positive data from its randomized, double-blind, placebo- and active-controlled Phase 2b trial of TRV130 in moderate ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Corporate News FDA Hot Corp. News Management Comments

Trevena (TRVN) Trades Near Day's High; Up 60%September 1, 2015 10:48 AM Barclays Upgrades Trevena (TRVN) to OverweightSeptember 1, 2015 10:44 AM Roth Capital Reiterates Buy on Trevena (TRVN) Following TRV130’s Phase 2b Results September 1, 2015 9:41 AM Needham & Company Reiterates Buy on Trevena (TRVN) Following Positive TRV130 Results September 1, 2015 8:45 AM Trevena (TRVN) PT Bumped to $14 at Cowen as TRV130 Shows Strong Safety And Efficacy ProfileSeptember 1, 2015 7:32 AM Trevena (TRVN) PT Raised to $20 at WedbushSeptember 1, 2015 6:44 AM Trevena Announces Positive Results from Phase 2b Study of TRV130 in Acute Postoperative PainAugust 31, 2015 4:01 PM